Briakinumab for the treatment of moderate to severe chronic plaque psoriasis (suspended)
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 November 2008
Topic area
  • Skin

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
23 February 2011 The Institute has been informed by the manufacturer that it has withdrawn its application for a centralised marketing authorisation for briakinumab, as the additional new data and analyses thought to be required for a favourable opinion could not be generated within the timeframe allowed in the centralised procedure. For further information please click on the following link:

NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual